DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This study will be conducted as a single-center, open-label, 2-period, single-sequence,
drug-drug interaction study to assess the effects of multiple-dose LX4211 400 mg (2 × 200-mg
tablets qd × 7 days) on the PK of single-dose rosuvastatin (1 × 10-mg tablet) in healthy male
and female subjects.